CTLA4 and melanoma: This outcome is supported by similar observations made in anti-PD-L1/CTLA-4-resistant melanoma and warrants the investigation into combinatorial treatment with the inhibitors of the PI3K and JAK/STAT pathway or VEGFR [78].